Abstract: Hypoxia, defi ned as a decrease of tissue oxygen levels, represents a fundamental pathophysiological condition in the microenvironment of solid tumors. Tumor hypoxia is known to be associated with radio/chemo-resistance and metastasis that eventually lead to cancer progression contributing to poor prognosis in cancer patients. Among transcription factors that accumulated under hypoxic conditions, hypoxia-inducible factor-1 (HIF-1) is a master transcription factor that has received the most intense attention in this field of research due to its capacity to modulate several hundred genes. With a clearer understanding of the HIF-1 pathway, eff orts are directed at manipulation of this complex genetic process in order to ultimately decrease cellular HIF-1 levels. Some novel agents have been shown to have HIF-1 inhibition activity through a variety of molecular mechanisms and have provided promising results in the preclinical setting.
Introduction
To grow beyond a diameter of approximately 1 mm, newly developing tumors must form their own vascular network and blood supply [1] . Angiogenesis is an adaptive response to tissue hypoxia [2] . Compared with the regular, ordered vasculature of normal tissues, blood vessels in tumors are oft en highly abnormal, with distended capillaries, leaky walls, and sluggish flow [3] . Tissue hypoxia results when supply of oxygen from the bloodstream does not meet demand from the cells in the tissue [4] . Protection against hypoxia in solid tumors is an important step in tumor development and progression [5] .
www.acbjournal.org http://dx.doi.org/10.5115/acb.2012. 45.2.73 to the classical tumor phenotypes of upregulated glycolysis and angiogenesis, leading to widespread interest in the HIF system as a target in cancer therapeutics [11] . Furthermore, studies indicate that hypoxia promotes genetic instability that leads to tumor progression [12] . Putra et al. [13] has provided evidence that functional polymorphisms in the HIF-1α gene may have an important impact on lung carcinogenesis, especially in adenocarcinomas, possibly by increasing genomic instability.
Hypoxia-Inducible Factors Family
To date, three HIFs (HIF-1, HIF-2, and HIF-3) have been identifi ed as regulating transcriptional programs in response to low oxygen levels [14] . HIF-1α is expressed ubiquitously in all cells, whereas HIF-2α and HIF-3α are selectively expressed in certain tissues, including vascular endothelial cells, type II pneumocytes, renal interstitial cells, liver parenchymal cells, and cells of the myeloid lineage [15] .
HIF-1 is a heterodimeric protein that is composed of HIF-1α and HIF-1β subunits. The amino terminal half of each subunit consists of basic helix-loop-helix and Per-ARNTSim (PAS) domains that mediate heterodimerization and DNA binding [16] . HIF-1α is subjected to O 2 -dependent hydroxylation on proline residue 402 and/or 564 by prolyl hydroxylase domain protein 2 and this modification creates an interface for interaction with the von Hippel-Lindau tumor suppressor protein, which recruits an E3 ubiquitinprotein ligase that catalyzes polyubiquitination of HIF-1α, thereby targeting it for proteasomal degradation [17] . During hypoxia, HIF-1α is stabilized and dimerized with HIF-1β, and the complex is translocated into the nucleus where it binds to hypoxia-responsive elements in the promoters or enhancers of the target genes, such as the genes encoding erythropoetin, glucose transporters, glycolytic enzymes, hemeoxygenase-1, inducible nitric oxide synthase, transferrin, and vascular endothelial growth factor (VEGF) [18] . HIF-1α protein expression is likely to be particularly sensitive to changes in the rate of synthesis because of its extremely short half-life under nonhypoxic conditions [19] .
HIF-2α has been associated with, and appears to promote, an undifferentiated phenotype in pluripotential cells [20] . HIF-2α (also known as EPAS-1, HLF) facilitates oxygen delivery and cellular adaptation to hypoxia by stimulating erythropoiesis, angiogenesis, and anaerobic glucose metabolism [21] . It has been shown that HIF-2α binds to the Oct-4 promoter and induces Oct-4 expression and transcriptional activity, thereby contributing to impaired development in homozygous HIF-2α KI/KI embryos, defective hematopoietic stem cell differentiation in embryoid bodies, and large embryonic stem cell-derived tumors characterized by altered cellular diff erentiation [22] . Furthermore, tumor hypoxia/HIF2α activation elicits an increase in epidermal growth factor receptor (EGFR) protein synthesis, and hence receptor expression, that is required for tumor cell growth autonomy [23] .
HIF-3α is expressed abundantly in lung epithelial cells, and the transcriptional induction of HIF-3α plays an important role in the response to hypoxia in vitro [24] . Moderate hypoxia induced mRNA transcription of HIF-3α whereas HIF-1α and HIF-2α mRNA levels remained unchanged [25] . As a very sensitive and rapidly reacting component of the HIF system, HIF-3α may therefore contribute to protection during early intervals of hypoxia and/or moderate hypoxia, while, in contrast, HIF-1α and HIF-2α may confer protection against severe and/or prolonged hypoxia [25] .
Hypoxia and HIF-1α
Tumor hypoxia has two sides. On the one hand, tissue O 2 concentrations of <1% (pO 2 <7 mm Hg) exert antiproliferative effects, restrict cell proliferation, promote diff erentiation, and may induce apoptosis and necrosis [26] . On the other hand, hypoxia is known to promote aggressive phenotypes of tumor and induces their invasiveness and metastasis [27] . When PC-3 cells and prostate cancer cell lines were exposed to 1% oxygen (hypoxia) for various periods of time, chronic hypoxia (≥24 hours) decreased cell proliferation and induced cell death. In contrast, the prostate cancer cells exposed to acute hypoxia (≤6 hours) displayed increased motility, clonogenic survival, and invasive capacity [28] .
The upregulation of HIF-1 is considered the molecular "switch" or "event" that is turned on by hypoxia [29] . However, stimulation of cells with a variety of growth factors and cytokines, including epidermal growth factor, fi broblast growth factor-2, heregulin, insulin, insulin-like growth factor 1 and 2, and interleukin-1b also induce the expression of HIF-1α protein, HIF-1 DNA-binding activity, and HIF-1 target gene expression under non-hypoxic conditions [30] .
As HIF-1 is a central transcription factor, once it is being upregulated, it will subsequently modulate the expression of many genes involved in cell metabolism, proliferation, Anat Cell Biol 2012;45:73-78 75 www.acbjournal.org apoptosis, and angiogenesis [31] . Recently, large-scale microarray approaches indicate that HIF-1 activates hundreds of target genes [32] . Activating HIF-1 usually means increased nuclear-HIF-1α expression. Although nuclear-HIF-1α expression has been reported to be the master of transcription factor, some study also revealed the importance of cytoplasmic-HIF-1α expression [33] .
Role of HIF-1 in Metastasis and Therapy Resistance
Severe and prolonged hypoxia may initiate apoptosis, whereas under acute and mild hypoxia, cells may adapt to this environmental stress and will survive [34] . Mounting evidence also suggests that hypoxic induces metastasis of hypoxia-surviving cancer cells. Cancer metastasis is mediated by the epithelial mesenchymal transition (EMT) process, by which cancer cells loss its epithelial markers and gain its mesencymal markers [35] . Loss or reduction of E-cadherin, an epithelial marker, expression is frequently observed at the invasive front of many advanced-stage human carcinomas [36] . Several lines of evidence suggest that hypoxia may be an important factor contributing to the loss of E-cadherin in solid tumors [37] .
Hypoxia has also led to therapeutic resistance through: 1) direct effects due to a lack of O 2 which some drugs and radiation require to be maximally cytotoxic; 2) indirect eff ects via altered cellular metabolism which decreases drug cytotoxicity, and; 3) enhanced genetic instability which can lead to more rapid development of drug resistant tumor cells [38] . The chemoresistance of hypoxic regions is a consequence, at least in part, of the low accessibility of the drug to these areas due to their poor vascularization [39] . As for radiotherapy, the biological eff ect of radiation depends on the degree of oxygenation, and hypoxic cells are approximately three-fold more resistant than well-oxygenated cells [40] . In one study, it has been demonstrated that hypoxia-induced chemoresistance to cisplatin and doxorubicin in non-small cell lung cancer (NSCLC) cells is through the HIF pathway and silencing of the HIF-1α gene reverses these drugs' resistance [41] .
HIF and Cancer Stem Cells
Recently, HIFs have been shown to activate specific signaling pathways such as Notch and activate the expression of transcription factors such as Oct-4 that control stem cell self-renewal and multipotency [42] . It has been reported that embryonal carcinoma cell lines showed faster proliferation when the culture was carried out under hypoxic (5% O 2 ) vs. normal (21% O 2 ) conditions [43] .
Using a novel cycling hypoxia-selected subpopulation from human breast cancer cell lines, Louie et al. [44] demonstrated that a stem-like breast cancer cell subpopulation could be expanded through repetitive hypoxia/reoxygenation cycles without genetic manipulation. Th ey also discovered that cells derived from this subpopulation can form colonies readily, are highly tumorigenic in immune-defi cient mice, and exhibit both stem-like and EMT phenotypes [44] .
HIF-1α-Targeted Therapy
With a clearer understanding of the HIF-1 pathway, efforts are directed at manipulation of this complex genetic process in order to ultimately decrease cellular HIF-1 levels. Inhibition of HIF-1 in animal model systems manifests decrease in tumorigenesis and increase in survival [45] . As HIF-1 has been found to regulate the shift within the tumor cells to anaerobic metabolism and to activate VEGF and angiogenesis, downregulation of the HIF-1 complex may suppress cancer progression [46] . Many approaches have been made to inhibit the expression or the transcriptional activity of HIF-1, such as genetic approaches and pharmacological approaches [47] . Meanwhile, there is a group of hypoxiaactivated prodrugs, which preferentially form cytotoxic and DNA-damaging free radicals under hypoxia, thus selectively eradicating hypoxic cells [48] . According to their putative mechanism of action, HIF-1 inhibitors could be tentatively divided into agents that modulate: 1) HIF-1α DNA binding; 2) HIF-1α mRNA expression; 3) HIF-1α protein degradation; 4) HIF-1α transcriptional activity; and 5) HIF-1α protein translation [49] .
HIF-1α DNA Binding Inhibition
Doxorubicin is known to have HIF-1 inhibition activity by blocking its binding to DNA [50] . Wang et al. [51] proposed a complex drug delivery system consisting of liposomes as a nano-carrier, doxorubicin as a cell death inducer, and antisense oligonucleotides targeted to HIF-1α mRNA as a suppressor of cellular resistance and angiogenesis. The system eff ectively delivers active ingredients into tumor cells, 
HIF-1α mRNA Expression Inhibition
EZN-2968 is a RNA antagonist composed of a thirdgeneration oligonucleotide that specifi cally binds and inhibits the expression of HIF-1α mRNA [52] . EZN-2968 has been reported to induce a potent, selective, and durable antagonism of HIF-1 mRNA and protein expression (IC50, 1-5 nmol/ L) under normoxic and hypoxic conditions associated with inhibition of tumor cell growth [52] . Another agent that disrupts HIF-1α mRNA expression is aminoflavone. Aminoflavone is a ligand of the aryl hydrocarbon receptor that has been shown to inhibit HIF-1α mRNA expression by ~50% [53] .
HIF-1α Protein Degradation
EGFR tyrosine kinase inhibitor, gefi tinib, has been shown to circumvent hypoxia-induced drug (cisplatin, paclitaxel and gemcitabine) resistance via the regulation of HIF-1α expression [54] . Th is action of gefi tinib was caused by reduced protein stability without any change in the level of HIF-1α mRNA. Interestingly, downregulation of HIF-1α has also been associated with positive therapeutic responses of cancer cells to EGFR-targeted therapy [55] .
Inhibition of HIF-1α Transcriptional Activity
Rapamycin has been shown to induce apoptosis in NSCLC cell lines through downregulation of survivin under hypoxic condition [56] . Pretreatment of PC-3 cells and prostate cancer cell lines with the rapamycin inhibited both the accumulation of HIF-1α and HIF-1-dependent transcriptional activity [57] . Another active substance that might fall into this 'transcription-inhibition category' is chetomin. Chetomin, a dithiodiketopiperazine metabolite of the fungus Chaetomium species, was known to have antimicrobial activity [58] . Systemic administration of chetomin inhibited hypoxiainducible transcription within tumors and inhibited tumor growth [59] . Meanwhile P3155, an HIF-1α inhibitor with antiangiogenic activity, showed specific HIF-1α inhibition with IC50 of 1.4 μM under hypoxia [60] . It suppressed HIF-1α expression as well as the phosphatidylinositol-3-kinase/ Akt pathway and abrogated expression of the HIF-1-inducible gene [60] .
HIF-1α Translation Inhibition
Selective inhibition of HIF-1 activation by using HIF-1α-targeted siRNA treatment reduces hypoxic radioresistance in vitro as effectively as a pharmacologic approach with chetomin as a small molecule blocking the HIF pathway [61] . In another study, HIF-1α siRNA-transfected glioma cell lines have decreased growth both in vitro and in vivo as well as proliferative index [62] .
Inhibition of HIF-1 has not always about therapeutic domain. Some studies have also investigated the possible benefit of HIF-1 inhibition for cancer prevention. Several natural products (e.g., resveratrol, genistein, apigenin, and berberin) have also been found to inhibit the activity of HIF-1 [63] . However, the use of HIF-1 inhibitors in cancer chemoprevention might be associated with toxicity [63] .
Conclusion
Hypoxia is a common pathophysiological occurrence with a profound impact on the cellular transcriptome [64] , and is undoubtedly an important mechanism of HIF activation in tumors [65] . HIF-1 is a master regulator of various target genes that plays critical roles in a multitude of pathways involved in the progression of cancer. The discovery of HIF-1 has increased enthusiasm for the investigation and development of targeted therapies modulating the cancer cell's response to the hypoxic microenvironment. Despite further needs of preclinical and clinical validation, HIF-1-targeted therapies, combined with radiotherapy and chemotherapy, are expected to be included in an integrated approach to cancer therapy in the future.
